Significant advancements in the early diagnosis and management of type 1 diabetes (T1D) have contributed to improved survival rates and enhanced quality of life. Despite this progress, T1D remains a complex chronic condition due to persistent complications and the need for continuous monitoring. This chapter highlights emerging approaches that are reshaping T1D prediction, prevention, and management. Periodic risk assessment and autoantibody screening have become essential tools for identifying individuals at risk before the onset of clinical symptoms, enabling presymptomatic intervention and more accurate disease prediction. In parallel, artificial intelligence (AI) is increasingly integrated into diabetes care, supporting real-time glucose monitoring and providing personalized insulin-dosing recommendations. Approaches such as the KNN-DSS algorithm exemplify AI’s utility in analyzing glucose fluctuations and mitigating risks of hyperglycemia and hypoglycemia. Beyond conventional insulin therapy, novel biomedical strategies are gaining prominence. Advances in artificial pancreas systems, gene therapy, stem cell-based therapies, and cell encapsulation technologies offer promising avenues for restoring endogenous insulin production and improving long-term disease control. Additionally, nano-drug delivery systems are emerging as a transformative option. By using nanoparticles to transport insulin or other therapeutic agents directly to targeted tissues, these systems enhance drug stability, absorption, and therapeutic precision while potentially reducing the need for frequent injections. Collectively, these innovations represent a shift from symptom-based treatment toward proactive prevention and individualized management of T1D. The integration of AI with next-generation therapeutic platforms, including nano-drug delivery, holds significant promise for the future of diabetes care.